Expanded Access Policy

Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections.

Patients with such antiviral diseases are the center of our focus. As a part of the drug development process, Atea is designing and conducting human clinical trials to evaluate the safety and efficacy of its investigational product candidates. The data from these trials will, if successful, be used to support applications for regulatory approval which in turn may lead to our product candidates becoming more readily available to patients.

At this time, participating in one of our clinical trials is the preferred way to access our investigational product candidates. As a result, Atea is currently unable to make its unapproved product candidates available on an expanded access basis.

While we do not currently offer investigational product candidates outside of our clinical trials, you and your physician may determine that enrolling in a clinical trial may be an option for you. For more information about Atea’s ongoing clinical trials, including whether or not enrollment is open and if there is an investigational site near you, please visit https://clinicaltrials.gov. Your physician may also contact Atea for clinical trial eligibility information by emailing us at [email protected].

If you have any questions about Atea’s expanded access policy, please contact [email protected]. We anticipate acknowledging receipt of any expanded access questions or requests within five business days of receipt.

As authorized by the 21^st Century Cures Act, Atea may revise this expanded access policy at any time. If there should be any policy change, we will update this policy and include a hyperlink to the relevant expanded access record(s) on https://clinicaltrials.gov after such records become active.